4 ms·

This might not be ethical, but given a psychedelic naive population, I wonder if the control could be given a non-serotonergic psychedelic such as salvinorin A.

This might not be ethical, but given a psychedelic naive population, I wonder if the control could be given a non-serotonergic psychedelic such as salvinorin A. There would definitely be a noticeable effect, but for someone who hasn't studied the effects of psilocybin, they may not realize it. The downside is that in order to keep the duration similar, you'd probably have to administer the salvinorin using an IV drip, and a six hour salvia trip could quite possibly be too traumatic.

parpfish 2y ago
It might be nice to also have a non-psychedelic non-sari as well. Right now a patient could use whether they tripped or not to determine exactly which treatment they received. But if you had the full 2x2 design of {drug has trip, drug has no trip} x {drug is supposedly therapeutic, drug is non therapeutic} the existence of a trip wouldn’t reveal their exact treatment